Abstract：
OBJECTIVE: This study evaluates the safety and efficacy of autologous adipose-derived mesenchymal stem cell-derived exosomes as a treatment for Psoriasis, a chronic immune-related skin and joint disorder, compared to current treatments like topicals, phototherapy, and systemic.
METHODS: The study isolated exosomes from Mesenchymal Stem Cells(MSCs) of healthy adipose tissue using ultracentrifugation. 12 patients with plaque psoriasis were divided into three groups and given single doses of exosomes. Tissue samples were collected pre- and post-treatment and examined for inflammatory(TNFα, IL23, IL17, IFNγ, CD3) and anti-inflammatory (FOXP3, IL10) markers. The severity of the lesion was also evaluated.
RESULTS: In this study, it was found that erythema and induration (P < 0.05) decreased significantly in patients receiving 200 μg. Still, this reduction in scaling was not significant, the thickness was significantly reduced in patients receiving 100 and 200 μg doses (P < 0.05). H&E evaluation showed that the decreasing trend in these patients was not significant (P > 0.05). IHC evaluation in patients receiving doses of 100 and 200 μg showed a decrease in the presence of IL17 (P < 0.05, <0.001) & CD3(P < 0.001, <0.05) and a considerable increase in FOXP3(P ≤ 0.001), in the tissue samples of the patients. Examining the expression of inflammatory factors also shows that dose 200 μg decreased the expression of IL17(P > 0.05), IFNγ(P > 0.05), IL23(P < 0.05), & TNFα(P ≤ 0.05) and increased the expression of the anti-inflammatory factor IL10(P < 0.05).
CONCLUSIONS: The study indicates that a 200 μg dose is optimal for patients, but a larger patient population is needed for more reliable results. Additionally, higher doses or multiple injections with specific intervals can increase confidence.
METHODS: The study isolated exosomes from Mesenchymal Stem Cells(MSCs) of healthy adipose tissue using ultracentrifugation. 12 patients with plaque psoriasis were divided into three groups and given single doses of exosomes. Tissue samples were collected pre- and post-treatment and examined for inflammatory(TNFα, IL23, IL17, IFNγ, CD3) and anti-inflammatory (FOXP3, IL10) markers. The severity of the lesion was also evaluated.
RESULTS: In this study, it was found that erythema and induration (P < 0.05) decreased significantly in patients receiving 200 μg. Still, this reduction in scaling was not significant, the thickness was significantly reduced in patients receiving 100 and 200 μg doses (P < 0.05). H&E evaluation showed that the decreasing trend in these patients was not significant (P > 0.05). IHC evaluation in patients receiving doses of 100 and 200 μg showed a decrease in the presence of IL17 (P < 0.05, <0.001) & CD3(P < 0.001, <0.05) and a considerable increase in FOXP3(P ≤ 0.001), in the tissue samples of the patients. Examining the expression of inflammatory factors also shows that dose 200 μg decreased the expression of IL17(P > 0.05), IFNγ(P > 0.05), IL23(P < 0.05), & TNFα(P ≤ 0.05) and increased the expression of the anti-inflammatory factor IL10(P < 0.05).
CONCLUSIONS: The study indicates that a 200 μg dose is optimal for patients, but a larger patient population is needed for more reliable results. Additionally, higher doses or multiple injections with specific intervals can increase confidence.
摘要：
目的：本研究评价自体脂肪间充质干细胞来源外泌体治疗银屑病的安全性和有效性。慢性免疫相关的皮肤和关节疾病,与目前的治疗方法如局部用药相比，光疗,和系统性。
方法：本研究使用超速离心从健康脂肪组织的间充质干细胞（MSC）中分离外泌体。将12例斑块型银屑病患者分为三组，给予单剂量外泌体治疗。在治疗前和治疗后收集组织样品，并检查炎症(TNFα，IL23,IL17,IFNγ,CD3）和抗炎（FOXP3，IL10）标记。还评估了病变的严重程度。
结果：在这项研究中，发现接受200μg的患者的红斑和硬结明显减少（P<0.05）。尽管如此，这种规模的减少并不显著，接受100和200μg剂量的患者的厚度显着降低（P<0.05）。H&E评价显示这些患者的下降趋势不显著(P>0.05)。在接受100和200μg剂量的患者中，IHC评估显示IL17（P<0.05，<0.001）和CD3（P<0.001，<0.05）的存在减少，FOXP3（P≤0.001）的显着增加，在患者的组织样本中。检测炎症因子的表达也显示200μg剂量降低了IL17的表达（P>0.05），IFNγ（P>0.05），IL23（P<0.05），和TNFα（P≤0.05），并增加抗炎因子IL10的表达（P<0.05）。
结论：该研究表明200μg剂量对患者是最佳的，但需要更大的患者群体才能获得更可靠的结果.此外,更高的剂量或具有特定间隔的多次注射可以增加置信度。
方法：本研究使用超速离心从健康脂肪组织的间充质干细胞（MSC）中分离外泌体。将12例斑块型银屑病患者分为三组，给予单剂量外泌体治疗。在治疗前和治疗后收集组织样品，并检查炎症(TNFα，IL23,IL17,IFNγ,CD3）和抗炎（FOXP3，IL10）标记。还评估了病变的严重程度。
结果：在这项研究中，发现接受200μg的患者的红斑和硬结明显减少（P<0.05）。尽管如此，这种规模的减少并不显著，接受100和200μg剂量的患者的厚度显着降低（P<0.05）。H&E评价显示这些患者的下降趋势不显著(P>0.05)。在接受100和200μg剂量的患者中，IHC评估显示IL17（P<0.05，<0.001）和CD3（P<0.001，<0.05）的存在减少，FOXP3（P≤0.001）的显着增加，在患者的组织样本中。检测炎症因子的表达也显示200μg剂量降低了IL17的表达（P>0.05），IFNγ（P>0.05），IL23（P<0.05），和TNFα（P≤0.05），并增加抗炎因子IL10的表达（P<0.05）。
结论：该研究表明200μg剂量对患者是最佳的，但需要更大的患者群体才能获得更可靠的结果.此外,更高的剂量或具有特定间隔的多次注射可以增加置信度。
